26 results found.

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Hematopoietic/Lymphoid Cancer, Non-hodgkin Lymphoma,B Cell, or Re Clinical Trial using Biological: anti-CD19-CAR vector-transduced T cells genetically engineered lymphocyte therapy

Chinese PLA General Hospital - Recruiting 50 years to 80 years.
- Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma.
Biological: anti-CD19-CAR vector-transduced T cells genetically engineered lymphocyte therapy

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Lo Clinical Trial using Everolimus and Rituximab

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas and Hodgkin's Lymphoma.
Everolimus and Rituximab

Mantle Cell Lymphoma Clinical Trial using LY2835219

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma.
LY2835219

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Clinical Trial using ofatumumab; cyclophosphamide; dexamethasone; doxorubicin hydrochloride; vincristine sulfate; cytarabine; autologous hematopoietic stem cell transplantation; methotrexate; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years to 69 years.
- Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma.
ofatumumab; cyclophosphamide; dexamethasone; doxorubicin hydrochloride; vincristine sulfate; cytarabine; autologous hematopoietic stem cell transplantation; methotrexate; laboratory biomarker analysis

Carcinoma, Renal Cell, or Lymphoma, Mantle-Cell Clinical Trial using Temsirolimus (Non-Interventional Study)

Pfizer - Recruiting 18 years or older.
- INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.
Temsirolimus (Non-Interventional Study)

Mantle Cell Lymphoma Clinical Trial using Bendamustine; Rituximab; Ibrutinib; Placebo

Janssen Research & Development, LLC - Recruiting 65 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma.
Bendamustine; Rituximab; Ibrutinib; Placebo

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Lymphoma Clinical Trial using rituximab; bendamustine hydrochloride; cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; leucovorin calcium; methotrexate; vincristine sulfate

Southwest Oncology Group - Recruiting 18 years to 65 years.
- A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ó 65 Years of Age With Previously Untreated Mantle Cell Lymphoma.
rituximab; bendamustine hydrochloride; cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; leucovorin calcium; methotrexate; vincristine sulfate

Lymphoma Clinical Trial using Carfilzomib; Lenalidomide; Rituximab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
Carfilzomib; Lenalidomide; Rituximab

Non-Hodgkin's Lymphoma (NHL) Clinical Trial using temsirolimus

Pfizer - Recruiting 18 years or older.
- A Randomized Phase 4 Study Comparing 2 Doses Of Intravenous Temsirolimus In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL).
temsirolimus

Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, or Gastro Clinical Trial using Temsirolimus; Sunitinib; Axitinib

Pfizer - Recruiting 18 years or older.
- STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Toriselr), Sunitinib (Sutentr), and Axitnib (Inlytar) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST).
Temsirolimus; Sunitinib; Axitinib

Chronic Lymphocytic Leukemia, or Mantle Cell Lymphoma Clinical Trial using Ublituximab; Ibrutinib

TG Therapeutics, Inc. - Recruiting 18 years or older.
- A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies.
Ublituximab; Ibrutinib

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Mantle Cell Lymphoma Clinical Trial using Ibrutinib; Temsirolimus

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy.
Ibrutinib; Temsirolimus

Mantle Cell Lymphoma Clinical Trial using Rituximab; bortezomib; Cladribine

Milton S. Hershey Medical Center - Recruiting 18 years or older.
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011).
Rituximab; bortezomib; Cladribine

Mantle Cell Lymphoma Clinical Trial using R-CHOP; R-CHOP / R-HAD; Rituximab; Lenalidomide

The Lymphoma Academic Research Organisation - Recruiting 60 years or older.
- Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma.
R-CHOP; R-CHOP / R-HAD; Rituximab; Lenalidomide

CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma Clinical Trial using rituximab

University Hospital Heidelberg - Recruiting 18 years or older.
- Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial.
rituximab

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multipl Clinical Trial using SNS01-T

Senesco Technologies, Inc. - Recruiting 18 years or older.
- Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma.
SNS01-T

Mantle Cell Lymphoma Clinical Trial using Rituximab; Bendamustine; Cytarabine

Dana-Farber Cancer Institute - Recruiting 18 years to 69 years.
- A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma.
Rituximab; Bendamustine; Cytarabine

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Fo Clinical Trial using PI3K inhibitor BKM120; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma.
PI3K inhibitor BKM120; laboratory biomarker analysis

Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, or SLL Clinical Trial using rituximab; bortezomib; cladribine

University of Arizona - Recruiting 18 years or older.
- A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas.
rituximab; bortezomib; cladribine